Fate Therapeutics Stock Forecast, Price & News

Fate Therapeutics' stock was trading at $23.79 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, FATE stock has increased by 86.6% and is now trading at $44.40.
View which stocks have been most impacted by COVID-19.

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fate Therapeutics in the last year. There are currently 1 hold rating and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Fate Therapeutics.

Fate Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Fate Therapeutics.

Fate Therapeutics, Inc. (NASDAQ:FATE) announced its quarterly earnings results on Wednesday, August, 5th. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.27) by $0.08. The biopharmaceutical company earned $5.47 million during the quarter, compared to analyst estimates of $20.33 million. Fate Therapeutics had a negative return on equity of 38.64% and a negative net margin of 881.86%.
View Fate Therapeutics' earnings history.

13 equities research analysts have issued twelve-month target prices for Fate Therapeutics' stock. Their forecasts range from $25.00 to $60.00. On average, they expect Fate Therapeutics' share price to reach $40.29 in the next year. This suggests that the stock has a possible downside of 9.3%.
View analysts' price targets for Fate Therapeutics.

Some companies that are related to Fate Therapeutics include argenx (ARGX), QIAGEN (QGEN), BIO-TECHNE (TECH), Neurocrine Biosciences (NBIX), Repligen (RGEN), Crispr Therapeutics (CRSP), Acceleron Pharma (XLRN), Adaptive Biotechnologies (ADPT), Momenta Pharmaceuticals (MNTA), Iovance Biotherapeutics (IOVA), Novavax (NVAX), Allogene Therapeutics (ALLO), China Biologic Products (CBPO), Denali Therapeutics (DNLI) and Kodiak Sciences (KOD).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Fate Therapeutics investors own include Cara Therapeutics (CARA), Crispr Therapeutics (CRSP), 1877 (JUNO), NVIDIA (NVDA), Sangamo Therapeutics (SGMO), Advanced Micro Devices (AMD), Exelixis (EXEL), Neurocrine Biosciences (NBIX), Sorrento Therapeutics (SRNE) and Gilead Sciences (GILD).

Fate Therapeutics trades on the NASDAQ under the ticker symbol "FATE."

Fate Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include ARK Investment Management LLC (1.66%), Columbus Circle Investors (0.28%), Assenagon Asset Management S.A. (0.10%), State of New Jersey Common Pension Fund D (0.07%), Epiq Partners LLC (0.04%) and DekaBank Deutsche Girozentrale (0.03%). Company insiders that own Fate Therapeutics stock include Amir Nashat, Bahram Valamehr, Cindy Tahl, Daniel D Shoemaker, J Scott Wolchko and Redmile Group, Llc.
View institutional ownership trends for Fate Therapeutics.

FATE stock was sold by a variety of institutional investors in the last quarter, including BNP Paribas Arbitrage SA, Columbus Circle Investors, State of New Jersey Common Pension Fund D, and Vigilare Wealth Management. Company insiders that have sold Fate Therapeutics company stock in the last year include Bahram Valamehr, Cindy Tahl, and J Scott Wolchko.
View insider buying and selling activity for Fate Therapeutics.

FATE stock was purchased by a variety of institutional investors in the last quarter, including ARK Investment Management LLC, Assenagon Asset Management S.A., Epiq Partners LLC, DekaBank Deutsche Girozentrale, Exchange Traded Concepts LLC, Bradley Foster & Sargent Inc. CT, Pacer Advisors Inc., and Nisa Investment Advisors LLC.
View insider buying and selling activity for Fate Therapeutics.

Shares of FATE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of FATE stock can currently be purchased for approximately $44.40.

Fate Therapeutics has a market capitalization of $3.86 billion and generates $10.68 million in revenue each year. The biopharmaceutical company earns $-98,150,000.00 in net income (profit) each year or ($1.44) on an earnings per share basis. Fate Therapeutics employs 178 workers across the globe.

The official website for Fate Therapeutics is www.fatetherapeutics.com.

Fate Therapeutics' mailing address is 3535 GENERAL ATOMICS COURT SUITE 200, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-875-1800 or via email at [email protected]